Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Founded in 2004 and headquartered in Villejuif, France, Predilife S.A. specializes in devising and commercializing sophisticated medical technologies and analytical models. The company's core offerings include preventative healthcare solutions and comprehensive breast screening tests. Among its notable products are MammoRisk, a diagnostic tool designed to forecast an individual's risk of developing breast cancer; DenSeeMammo, software for evaluating breast tissue density; and a specialized medical device developed for predicting prostate cancer risk.
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.